- Details
- In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part one of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer. For patients with metastatic castration-resistant...
|
- Details
- Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine VISION trial publication entitled, "Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." In the VISION trial, radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive me...
|
- Details
- In this UroToday Journal Club with Christopher Wallis and Zachary Klaassen, discuss a recent publication, “Identifying the Best Candidates for PSMA PET/CT as the Primary Staging Approach Among Men with High-Risk Prostate Cancer and Negative Conventional Imaging”. This conversation kicks off with a background on imaging as a critical component of prostate cancer care. They discuss the ProPSMA trial...
|
- Details
- In this UroToday Journal Club between Christopher Wallis and Zachary Klaassen, discuss the publication titled “Lutetium-177-PSMA Therapy for Men with Advanced Prostate Cancer: 18 Months Survival Analysis in a Single Australian Tertiary Institution”. This Journal Club kicks off with a background, and evolution, of metastatic castration-resistant prostate cancer (mCRPC). Dr. Wallis then goes on to d...
|
- Details
- Christopher Wallis and Zachary Klaassen review the NCCN clinical practice guidelines on prostate cancer. This discussion is the third part of their discussion of androgen deprivation therapy (ADT). Dr. Wallis begins this discussion with a conversation on intermittent vs continuous ADT for patients with prostate cancer. He examines the quality of life in conjunction with survival measurements. Abou...
|
- Details
- In this UroToday discussion between Zachary Klaassen and Christopher Wallis, the pair discuss the NCCN clinical practice guidelines in oncology, specifically looking at prostate cancer. This part of the conversation specifically looks at androgen deprivation therapy (ADT) for castration-naive disease. Dr. Klaassen begins by discussing the different categories that ADT has been categorized into rec...
|
- Details
- In this UroToday journal club, Christopher Wallis and Zachary Klaassen discuss the publication entitled “Is Prostate Cancer-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-Effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial”. The conversation begins with a discussion about the importance of imaging in the treatment timeline of prostate ca...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “18F-Fluciclovine-PET/CT Imaging versus Conventional Imaging Alone to Guide Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer, the EMPIRE-1 Study”. This Journal Club kicks off with a discussion about adjuvant radiotherapy in patients with prostate cancer. Dr. Wallis discusses how adjuvant radiotherapy improves bioche...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma . The discussion begins with a history of the targeted therapy era, progressing into the introduction of combination approaches, beginning...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a recently published paper, entitled, “ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.” They discuss the basics of circulating tumor DNA (ctDNA). He specifically discusses how we can use ctDNA to identify molecularly, or microscopic, residual disease. The study shows that ctDNA-positive patients with adjuvant atezolizumab, after surgery...
|
